EMEA-001219-PIP01-11-M04

Key facts

Invented name
Triumeq
Active substance
  • dolutegravir
  • abacavir
  • lamivudine
Therapeutic area
Infectious diseases
Decision number
P/0018/2019
PIP number
EMEA-001219-PIP01-11-M04
Pharmaceutical form(s)
  • Film-coated tablet
  • Dispersible tablet
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries
ViiV Healthcare UK Limited
United Kingdom
Tel. +44 2089902426
E-mail: eu.paediatric-plans@gsk.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating